Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Depo-provera
Generic Name Medroxyprogesterone
Other Brand Name Depo-provera
Packing 1ml
Manufacturer Pharmacia-Upjohn, Pfizer
Form Vial
Strength 150mg/ml
Country India, Turkey

  • 1 x 1ml 150mg Vial $8.97
Available online
More Views

Customers also bought

  • Generic Nasonex, Mometasone Fumerate Nasal Spray

    Generic Name:Mometasone Fumerate
    Form:100 mdi
  • Generic Zanaflex, Tizanidine

    Generic Name:Tizanidine
    Form:Tablet
  • Augmentin, Amoxicillin/ Clavulanate Potassium

    Generic Name:Amoxicillin/ Clavulanate Potassium
    Form:Tablet, Injection
  • Premarin, Conjugated Estrogens

    Generic Name:Conjugated Estrogen
    Form:Tablet
  • Carodyl

    Generic Name:Carprofen
    Form:Chewable Tablet
  • Guaifenesin

    Generic Name: Guaifenesin
    Form: Tablets
< >

1 1 1 1 1 1

Similar Product

  • Generic Provera, Medroxyprogestrone Acetate

    Generic Name:Medroxyprogestrone Acetate
    Form:Tablet
  • Modus, Medroxyprogesterone

    Generic Name:Medroxyprogesterone
    Form:Tablet
    Out of Stock
  • Maxogest, Medroxyprogesterone

    Generic Name:Medroxyprogesterone
    Form:Tablet
  • Premique Low Dose MR

    Generic Name:Conjugated Oestrogens/ Medroxyprogesterone
    Form:tab
< >

1 1 1 1

Details

Introduction

Medroxyprogesterone is a drug that functions as a progestin. An acylated mixture, Medroxyprogesterone 17-acetate is scientifically used in pharmaceuticals.In comparison to Medroxyprogesterone 17-acetate (MPA), Medroxyprogesterone is just about 100 flip less effective as a progestin.


Use

Medroxyprogesterone Contraceptive Injection (medroxyprogesterone acetate), the recommended dose for women every 3 months, inhibits gonadotropin secretion by inhibiting follicular maturation and ovulation and causing thinning of the endometrium. These actions determine the contraceptive effect.


Side effects

The following adverse reactions have been reported in 5% of subjects: irregular menstrual cycle (bleeding or amenorrhea, or both), headache, nervousness; pain or discomfort, Dizziness, Asthenia (weakness or fatigue). Adverse reactions reported in 1 to 5% of subjects who used Medroxyprogesterone injections were: Decreased libido or lack of orgasm, back pain, leg cramps, depression, nausea, insomnia, leucorrhoea, acne, vaginitis, pelvic pain; breast pain, alopecia or no hair growth, bloating sensations, rash, edema, flushing. Reactions reported in less than 1% of the subjects included: galactorrhea, melasma, chloasma, convulsions, changes in appetite, gastrointestinal disturbances, jaundice, genitourinary infections, vaginal cysts, dyspareunia, paresthesia, chest pain, pulmonary embolism, Allergic reactions, anemia, drowsiness, syncope, dyspnea and asthma, tachycardia, fever, sweating with particular odor, dry skin, chills, increased libido, excessive thirst, hoarseness, local pain (at the injection site), blood dyscrasias , rectal bleeding, change in breast size, breast lumps or nipple bleeding mammary tumor in the armpit, breast cancer, prevention of lactation, sensation of pregnancy, inability to resume fertility, paralysis, facial palsy, scleroderma, osteoporosis, uterine hyperplasia, cervical cancer, varicose veins, dysmenorrhea, hirsutism, accidental pregnancy, thrombophlebitis, deep vein thrombosis.


Contraindication

Known or suspected pregnancy or as a diagnostic test for pregnancy. Undiagnosed vaginal bleeding. Known or suspected breast cancer.


storage

. Keep out of reach and sight of children. . Don't use after the expiry date (EXP) printed on the carton. . Unopened vial: Store at temperatures below 30° C.


Composition

Each ml contains: . Medroxyprogesterone acetate - 150 mg . -28.9 Mg polyethylene glycol 3350 . Polysorbate 80 to 2.41 mg . Sodium chloride - 68 mg . -1.37 Mg methylparaben . Propylparaben - 0.150 mg . Sterile water q.s.


Important Precautions

Irregular bleeding: Most women using Medroxyprogesterone injections present with changes in menstrual bleeding. Changes in bone density: Using Medroxyprogesterone injection may be considered among the risk factors for developing osteoporosis. The degree of bone loss is greater in early years of use and then approaches the normal rate. Risk of malignancy: Long-term surveillance of women who use Medroxyprogesterone injection has demonstrated a slightly increased or unchanged overall risk of breast cancer and no increased risk for ovarian cancer, cervical cancer and liver protective effects. Thromboembolic disease: Physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular disease or thrombosis). Ocular diseases: Medication should not be re-administered during the examination, if there is sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia or migraine. increased risk of low birth weight, which in turn is associated with increased risk of neonatal exitus. Ectopic pregnancy: Health professionals need to consider the possibility of an ectopic pregnancy in women who use Medroxyprogesterone injection and get pregnant or complain of severe abdominal pain. Lactation: Detectable amounts of drug were found in breast milk in women who use Medroxyprogesterone. In nursing mothers treated with Medroxyprogesterone, qualitative and quantitative composition of milk is not affected. Anaphylaxis and anaphylactic reactions: When using Medroxyprogesterone injections, patients reported anaphylactic reactions.


Dosage and administration

1 ml vial of Medroxyprogesterone Contraceptive Injection should be shaken well immediately before use to ensure that the dose to be administered represents a uniform suspension. The recommended dose is 150 mg Medroxyprogesterone injections, administered intramuscularly every 3 months injected deep into gluteal muscle or calf muscle. To increase the assurance that the patient is not pregnant at the time of administration, it is recommended that the injection should be given in the first 5 days of normal menstrual cycle beginning at 5 days postpartum if not breastfeeding and at 6 weeks postpartum if breastfeeding. If the period between cycles is less than 14 weeks, the doctor must examine whether or not the patient was pregnant before taking the medicine.